Although we have detected pSRC as a target of Niraparib, it remains to be determined whether Niraparib regulates other kinases activated in ovarian or pancreatic cancer cells to impact STAT3 activity and increase Niraparib’s antitumor effects. Here, STAT3 is linked to familial pancreatic carcinoma.